Efficacy and safety of alemtuzumab, daclizumab and antithymocyte globulin in kidney transplantation
10.3969/j.issn.2095-4344.2015.02.027
- VernacularTitle:阿伦和达珠单抗与抗胸腺蛋白对肾移植的有效性及安全性比较
- Author:
Tao WANG
;
Wenjing HAO
;
Huantao ZONG
;
Yong ZHANG
- Publication Type:Journal Article
- Keywords:
Immunosuppressive Agents;
Kidney Transplantation;
Organ Transplantation
- From:
Chinese Journal of Tissue Engineering Research
2015;(2):305-309
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Immunosuppressants fight against acute rejections by influencing humoral and celular immune to suppress the immune function, and then improve patient/renal graft survival. OBJECTIVE:To evaluate the effectiveness and safety of alemtuzumab, daclizumab and antithymocyte globulin in inducing immunosuppression in kidney transplantation. METHODS:The randomized controled trials of alemtuzumab or daclizumabversusATG in kidney tranplantation published from 1966 to 2011 were enroled by searching PubMed and EMBASE using Cochrane systematic review. We colected data and major outcomes. And a meta-analysis was conducted on homogeneous studies. RESULTS AND CONCLUSION: A total of 9 randomized controled trials (777 patients) about kidney transplantation were included. The meta-analysis results showed that the safety items including patient/renal graft survival and acute rejection at a folow-up of 24 months had no statistical differences among the three drugs (al P > 0.05). But there was a significant difference between the infection rates of alemtuzumab and antithymocyte globulin at 36 months of folow-up (P < 0.05). The results indicate that alemtuzumab, daclizumab and antithymocyte globulin are equaly effective in inducing immunosuppression at a folow-up of 24 months in kidney transplantation. However, compared to antithymocyte globulin, alemtuzumab has a lower rate of infection at a folow-up of 36 months.
